[96a5a0]: / output / allTrials / identified / NCT04808531_identified.json

Download this file

838 lines (838 with data), 37.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
{
"info": {
"nct_id": "NCT04808531",
"official_title": "NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial",
"inclusion_criteria": "At Screening Phase\n\nParticipants must fulfil all of the following criteria:\n\n* Prospective male and female participants that are:\n\n 1. in the age range 18-65 years or\n 2. 65 to 75 years without significant co-morbidities (heart, lung, liver or renal failure, myocardial infarction, cerebral vascular accident, peripheral vascular disease, chronic obstructive pulmonary disease, dementia, connective tissue disease or diabetes mellitus with end-organ damage)\n* Metastatic bone pain from a cancer diagnosis is the only major cause of pain.\n* Documented proof (imaging) confirming the Metastatic Bone Disease at the current site of pain and that there has no been treatment since diagnosis\n* Meet International Classification of Diseases, Tenth Revision (ICD-10) codes for pain management criteria (i.e., bone cancer pain)\n* During the screening period, the participant is on stable opioid pain management and pain severity (NPRS) ≤ 8 with a maximum variation of ± 1\n* Pain Detect score > 18\n* Participant willing and able to provide informed consent and follow study procedures\n\n 1. including agreeing to not drive or operate heavy machinery; and\n 2. females of child-bearing potential agree to use reliable contraception during the duration of the clinical trial\n* Patient deemed tolerable to Oxycodone and NanaBis™ determined by medical history of allergies to cannabinoids or opioids\n* Patient must not be a participant in a clinical trial or study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
"exclusion_criteria": "At Screening Phase\n\nParticipants will be excluded if they meet any of the following criteria that include:\n\n* History of epilepsy or recurrent seizures\n* Moderate to severe medical conditions such as\n\n 1. Severe hepatic, cardiovascular, pulmonary or renal impairment or\n 2. Psychiatric disorders (i.e., unstable schizophrenia, recent drug-induced psychosis, severe mood disorders), that would be assessed at the medical screen\n* If participants have been diagnosed with a current substance abuse disorder\n* Women who are pregnant, lactating or planning to become pregnant\n* Identified concerns by the nursing / medical team relevant to the safe storage of medications (i.e., NanaBis™ or standard medical therapy)\n* Participants who may not be available for follow up (i.e., planned or expected travel or other)\n* Participants plan to undergo any treatment that will substantially reduce the burden of disease (and therefore bone pain) during the screening, titration or maintenance phase of the clinical trial such as radiotherapy or cytotoxic chemotherapy\n* Participants who are unable to withhold all analgesia (apart from which is part of this trial) during the titration and maintenance phase of the study, including bisphosphonates, or are currently exceeding equivalence of 70mg BD Oxycodone CR. Medications such as bisphosphonates may be coordinated so they are given either side of the excluded period that covers the titration and maintenance phases\n* Participants will NOT be excluded if they are being treated with maintenance pharmacotherapy to prevent progression of disease such as steroids and hormone therapy, which may be continued during the trial at a stable dose\n* Participant will be excluded if they are participating in any other clinical trial or study.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Prospective male and female participants that are:",
"criterions": [
{
"exact_snippets": "male and female",
"criterion": "gender",
"requirements": [
{
"requirement_type": "allowed_values",
"expected_value": [
"male",
"female"
]
}
]
}
]
},
{
"line": "1. in the age range 18-65 years or",
"criterions": [
{
"exact_snippets": "age range 18-65 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 65,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "2. 65 to 75 years without significant co-morbidities (heart, lung, liver or renal failure, myocardial infarction, cerebral vascular accident, peripheral vascular disease, chronic obstructive pulmonary disease, dementia, connective tissue disease or diabetes mellitus with end-organ damage)",
"criterions": [
{
"exact_snippets": "65 to 75 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 65,
"unit": "years"
},
{
"operator": "<=",
"value": 75,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "without significant co-morbidities",
"criterion": "significant co-morbidities",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "heart ... failure",
"criterion": "heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "lung ... failure",
"criterion": "lung failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "liver ... failure",
"criterion": "liver failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "renal failure",
"criterion": "renal failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "myocardial infarction",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "cerebral vascular accident",
"criterion": "cerebral vascular accident",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "peripheral vascular disease",
"criterion": "peripheral vascular disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "chronic obstructive pulmonary disease",
"criterion": "chronic obstructive pulmonary disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "dementia",
"criterion": "dementia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "connective tissue disease",
"criterion": "connective tissue disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "diabetes mellitus with end-organ damage",
"criterion": "diabetes mellitus with end-organ damage",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Metastatic bone pain from a cancer diagnosis is the only major cause of pain.",
"criterions": [
{
"exact_snippets": "Metastatic bone pain from a cancer diagnosis is the only major cause of pain.",
"criterion": "metastatic bone pain",
"requirements": [
{
"requirement_type": "cause of pain",
"expected_value": "only major cause"
}
]
}
]
},
{
"line": "* Documented proof (imaging) confirming the Metastatic Bone Disease at the current site of pain and that there has no been treatment since diagnosis",
"criterions": [
{
"exact_snippets": "Documented proof (imaging) confirming the Metastatic Bone Disease",
"criterion": "Metastatic Bone Disease",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
}
]
},
{
"exact_snippets": "there has no been treatment since diagnosis",
"criterion": "treatment since diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Meet International Classification of Diseases, Tenth Revision (ICD-10) codes for pain management criteria (i.e., bone cancer pain)",
"criterions": [
{
"exact_snippets": "Meet International Classification of Diseases, Tenth Revision (ICD-10) codes for pain management criteria",
"criterion": "ICD-10 codes for pain management",
"requirements": [
{
"requirement_type": "compliance",
"expected_value": true
}
]
},
{
"exact_snippets": "bone cancer pain",
"criterion": "bone cancer pain",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* During the screening period, the participant is on stable opioid pain management and pain severity (NPRS) ≤ 8 with a maximum variation of ± 1",
"criterions": [
{
"exact_snippets": "During the screening period, the participant is on stable opioid pain management",
"criterion": "opioid pain management",
"requirements": [
{
"requirement_type": "stability",
"expected_value": true
}
]
},
{
"exact_snippets": "pain severity (NPRS) ≤ 8",
"criterion": "pain severity (NPRS)",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 8,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "pain severity (NPRS) ... maximum variation of ± 1",
"criterion": "pain severity (NPRS)",
"requirements": [
{
"requirement_type": "variation",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Pain Detect score > 18",
"criterions": [
{
"exact_snippets": "Pain Detect score > 18",
"criterion": "Pain Detect score",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 18,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Participant willing and able to provide informed consent and follow study procedures",
"criterions": [
{
"exact_snippets": "Participant willing and able to provide informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
},
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "Participant ... able to ... follow study procedures",
"criterion": "ability to follow study procedures",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "1. including agreeing to not drive or operate heavy machinery; and",
"criterions": [
{
"exact_snippets": "agreeing to not drive",
"criterion": "driving",
"requirements": [
{
"requirement_type": "agreement",
"expected_value": false
}
]
},
{
"exact_snippets": "agreeing to not ... operate heavy machinery",
"criterion": "operating heavy machinery",
"requirements": [
{
"requirement_type": "agreement",
"expected_value": false
}
]
}
]
},
{
"line": "2. females of child-bearing potential agree to use reliable contraception during the duration of the clinical trial",
"criterions": [
{
"exact_snippets": "females of child-bearing potential",
"criterion": "gender and reproductive status",
"requirements": [
{
"requirement_type": "gender",
"expected_value": "female"
},
{
"requirement_type": "reproductive status",
"expected_value": "child-bearing potential"
}
]
},
{
"exact_snippets": "agree to use reliable contraception during the duration of the clinical trial",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "agreement",
"expected_value": true
},
{
"requirement_type": "duration",
"expected_value": "during the duration of the clinical trial"
}
]
}
]
},
{
"line": "* Patient deemed tolerable to Oxycodone and NanaBis™ determined by medical history of allergies to cannabinoids or opioids",
"criterions": [
{
"exact_snippets": "Patient deemed tolerable to Oxycodone",
"criterion": "Oxycodone tolerance",
"requirements": [
{
"requirement_type": "tolerance",
"expected_value": true
}
]
},
{
"exact_snippets": "tolerable to ... NanaBis™",
"criterion": "NanaBis™ tolerance",
"requirements": [
{
"requirement_type": "tolerance",
"expected_value": true
}
]
},
{
"exact_snippets": "medical history of allergies to cannabinoids",
"criterion": "allergies to cannabinoids",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "medical history of allergies to ... opioids",
"criterion": "allergies to opioids",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patient must not be a participant in a clinical trial or study.",
"criterions": [
{
"exact_snippets": "Patient must not be a participant in a clinical trial or study.",
"criterion": "participation in a clinical trial or study",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 75 Years",
"criterions": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* History of epilepsy or recurrent seizures",
"criterions": [
{
"exact_snippets": "History of epilepsy",
"criterion": "epilepsy",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "recurrent seizures",
"criterion": "seizures",
"requirements": [
{
"requirement_type": "recurrence",
"expected_value": true
}
]
}
]
},
{
"line": "* Moderate to severe medical conditions such as",
"criterions": [
{
"exact_snippets": "Moderate to severe medical conditions",
"criterion": "medical conditions",
"requirements": [
{
"requirement_type": "severity",
"expected_value": [
"moderate",
"severe"
]
}
]
}
]
},
{
"line": "1. Severe hepatic, cardiovascular, pulmonary or renal impairment or",
"criterions": [
{
"exact_snippets": "Severe hepatic ... impairment",
"criterion": "hepatic impairment",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
},
{
"exact_snippets": "Severe ... cardiovascular ... impairment",
"criterion": "cardiovascular impairment",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
},
{
"exact_snippets": "Severe ... pulmonary ... impairment",
"criterion": "pulmonary impairment",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
},
{
"exact_snippets": "Severe ... renal impairment",
"criterion": "renal impairment",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
}
]
},
{
"line": "2. Psychiatric disorders (i.e., unstable schizophrenia, recent drug-induced psychosis, severe mood disorders), that would be assessed at the medical screen",
"criterions": [
{
"exact_snippets": "Psychiatric disorders (i.e., unstable schizophrenia, recent drug-induced psychosis, severe mood disorders)",
"criterion": "psychiatric disorders",
"requirements": [
{
"requirement_type": "types",
"expected_value": [
"unstable schizophrenia",
"recent drug-induced psychosis",
"severe mood disorders"
]
}
]
}
]
},
{
"line": "* If participants have been diagnosed with a current substance abuse disorder",
"criterions": [
{
"exact_snippets": "diagnosed with a current substance abuse disorder",
"criterion": "substance abuse disorder",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
},
{
"requirement_type": "current",
"expected_value": true
}
]
}
]
},
{
"line": "* Women who are pregnant, lactating or planning to become pregnant",
"criterions": [
{
"exact_snippets": "Women who are pregnant",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "pregnant"
}
]
},
{
"exact_snippets": "lactating",
"criterion": "lactation status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "lactating"
}
]
},
{
"exact_snippets": "planning to become pregnant",
"criterion": "pregnancy intention",
"requirements": [
{
"requirement_type": "intention",
"expected_value": "planning to become pregnant"
}
]
}
]
},
{
"line": "* Identified concerns by the nursing / medical team relevant to the safe storage of medications (i.e., NanaBis™ or standard medical therapy)",
"criterions": [
{
"exact_snippets": "Identified concerns by the nursing / medical team relevant to the safe storage of medications",
"criterion": "concerns about safe storage of medications",
"requirements": [
{
"requirement_type": "identification",
"expected_value": true
}
]
}
]
},
{
"line": "* Participants who may not be available for follow up (i.e., planned or expected travel or other)",
"criterions": [
{
"exact_snippets": "Participants who may not be available for follow up",
"criterion": "availability for follow up",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
}
]
},
{
"line": "* Participants plan to undergo any treatment that will substantially reduce the burden of disease (and therefore bone pain) during the screening, titration or maintenance phase of the clinical trial such as radiotherapy or cytotoxic chemotherapy",
"criterions": [
{
"exact_snippets": "Participants plan to undergo any treatment that will substantially reduce the burden of disease ... such as radiotherapy or cytotoxic chemotherapy",
"criterion": "treatment plan",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"radiotherapy",
"cytotoxic chemotherapy"
]
},
{
"requirement_type": "effect",
"expected_value": "substantially reduce the burden of disease"
}
]
}
]
},
{
"line": "* Participants who are unable to withhold all analgesia (apart from which is part of this trial) during the titration and maintenance phase of the study, including bisphosphonates, or are currently exceeding equivalence of 70mg BD Oxycodone CR. Medications such as bisphosphonates may be coordinated so they are given either side of the excluded period that covers the titration and maintenance phases",
"criterions": [
{
"exact_snippets": "Participants who are unable to withhold all analgesia ... during the titration and maintenance phase of the study",
"criterion": "ability to withhold analgesia",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "currently exceeding equivalence of 70mg BD Oxycodone CR",
"criterion": "Oxycodone CR dosage",
"requirements": [
{
"requirement_type": "dosage",
"expected_value": {
"operator": "<=",
"value": 70,
"unit": "mg BD"
}
}
]
}
]
},
{
"line": "* Participants will NOT be excluded if they are being treated with maintenance pharmacotherapy to prevent progression of disease such as steroids and hormone therapy, which may be continued during the trial at a stable dose",
"criterions": [
{
"exact_snippets": "being treated with maintenance pharmacotherapy to prevent progression of disease such as steroids and hormone therapy",
"criterion": "maintenance pharmacotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "may be continued during the trial at a stable dose",
"criterion": "stable dose",
"requirements": [
{
"requirement_type": "stability",
"expected_value": true
}
]
}
]
},
{
"line": "* Participant will be excluded if they are participating in any other clinical trial or study.",
"criterions": [
{
"exact_snippets": "participating in any other clinical trial or study",
"criterion": "participation in other clinical trials or studies",
"requirements": [
{
"requirement_type": "participation",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"line": "At Screening Phase",
"criterions": []
},
{
"line": "Participants must fulfil all of the following criteria:",
"criterions": []
}
],
"failed_exclusion": [
{
"line": "At Screening Phase",
"criterions": []
},
{
"line": "Participants will be excluded if they meet any of the following criteria that include:",
"criterions": []
}
],
"failed_miscellaneous": []
}